Apex Benefits Hosts High-Cost Medications Event to Feature Lilly, Cigna and Swiss Re Executives
Free Event About the Impact of High-Cost Pharmacy Claims Targets Employer Education
Business professionals are invited to join Apex Benefits and global pharmaceutical and health industry leaders for “A Prescription for Managing the Impact of High Cost Medications” on November 13, 2019 at the Biltwell Event Center in Indianapolis.
For 85 percent of employers, pharmacy pricing is their predominant concern going into 2020, according to the National Business Group on Health (NBGH). The Apex program is a discussion of factors impacting the cost of medications across the pharmaceutical supply chain from drug manufacturers, health insurers and pharmacy benefit management companies to the employers and their employees.
HR Technology News: Genpact to Acquire Industry-Leading Digital Consultancy, Rightpoint
Featured speakers include Enrique Conterno, Senior Vice President of Diabetes Care at Eli Lilly and Company and President of LillyUSA; Steve Miller, M.D., Chief Clinical Officer of Cigna including the health insurer’s Express Scripts business unit; Joseph Byers, Vice President of Business Development for Swiss Re Corporate Solutions; and Jim Harenberg, Apex Vice President of Strategic Solutions and ApexRx Pharmacy Benefits Consulting. The event will be hosted by Apex General Counsel and Vice President of External Affairs Todd Rokita.
“Whether you work in Human Resources and have direct responsibility for managing benefits or if you feel the burden of providing the best programs to employees at the most affordable costs, you should attend this program,” says Rokita.
HR Technology News: Slack Strengthens Ties with Salesforce to Further Unlock Workplace Collaboration Opportunities
“These cost concerns will persist as large numbers of high-cost specialty medications and gene therapies come to market to treat cancer and debilitating chronic illnesses such as multiple sclerosis, rheumatoid arthritis, diabetes and heart disease,” Harenberg says.
With some of these drugs expected to cost hundreds of thousands of dollars per year and potentially millions of dollars per treatment, employer education and thoughtful planning are important.
“Just one unexpected diagnosis resulting in a high-cost drug therapy can wreak absolute havoc on an employer’s finances, not to mention its employee’s financial and physical health,” Harenberg states.
HR Technology News: US Workers Are Eager to Take on More Responsibility, but Management Is Standing in the Way